Takeda Gets GI Candidate – And Possibly Company – In Altos Deal
This article was originally published in PharmAsia News
In the latest in a string of deals, Takeda's agreement to acquire global rights to Altos's gastroparesis candidate - and possibly the company itself - gives the Japanese giant another asset in its core gastrointestinal area.
You may also be interested in...
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.